Bio-Rad Laboratories (BIO-B) Non-Current Deferred Tax Liability (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $881.8 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $881.8 million, up 4.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $881.8 million (up 4.88% YoY), and the FY2025 annual result was $1.1 billion, up 14.26% from the prior year.
• Non-Current Deferred Tax Liability retreated to $881.8 million in Q1 2026 per BIO-B's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $2.0 billion in Q1 2022 and troughed at $840.8 million in Q1 2025.
• A 5-year average of $1.3 billion and a median of $1.4 billion in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability plunged 58.41% in 2022, then advanced 14.26% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 billion in 2022, then declined by 7.16% to $1.6 billion in 2023, then sank by 43.59% to $927.2 million in 2024, then increased by 14.26% to $1.1 billion in 2025, then fell by 16.76% to $881.8 million in 2026.
• Business Quant data shows BIO-B's Non-Current Deferred Tax Liability at $881.8 million in Q1 2026, $1.1 billion in Q4 2025, and $872.6 million in Q3 2025.